Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Axogen Inc (AXGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 934,066
  • Shares Outstanding, K 34,090
  • Annual Sales, $ 41,110 K
  • Annual Income, $ -14,410 K
  • 36-Month Beta 0.40
  • Price/Sales 16.48
  • Price/Cash Flow N/A
  • Price/Book 86.25

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.55 +4.71%
on 01/17/18
31.70 -12.30%
on 01/08/18
+0.30 (+1.09%)
since 12/19/17
3-Month
19.75 +40.76%
on 10/23/17
31.70 -12.30%
on 01/08/18
+7.90 (+39.70%)
since 10/19/17
52-Week
8.75 +217.71%
on 01/23/17
31.70 -12.30%
on 01/08/18
+17.90 (+180.81%)
since 01/19/17

Most Recent Stories

More News
AxoGen, Inc. Preannounces Estimated Fourth Quarter and Full Year 2017 Revenue

Q4 Revenue will be at least $16.5 million, representing 45% growth over prior year

AXGN : 27.85 (+1.64%)
AxoGen Corporation Announces Avance(R) Nerve Graft Recipient Selected to Ride on Donate Life Rose Parade(R) Float

AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Dylan Harvey was selected to ride on the 2018 Donate...

AXGN : 27.85 (+1.64%)
AxoGen Announces Closing of Public Offering of Common Stock

AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve damage, today announced the closing of its previously announced underwritten public...

AXGN : 27.85 (+1.64%)
AxoGen, Inc. (Nasdaq: AXGN) to Ring The Nasdaq Stock Market Opening Bell

What:

AXGN : 27.85 (+1.64%)
NDAQ : 79.86 (+0.04%)
AxoGen Advances its Platform for Nerve Repair at Annual Analyst and Investor Day

Company Announces Expanded Application to Address Breast Reconstruction Neurotization Following Mastectomy

AXGN : 27.85 (+1.64%)
AxoGen, Inc. Announces Pricing of Public Offering of Common Stock

AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the repair of peripheral nerve damage, announced today that it has priced an underwritten public...

AXGN : 27.85 (+1.64%)
AxoGen, Inc. to Present at the 29th Annual Piper Jaffray Healthcare Conference

AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, President and Chief Executive Officer,...

AXGN : 27.85 (+1.64%)
AxoGen to Host Second Annual Analyst and Investor Day on November 20, 2017

AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the repair of peripheral nerve damage, today announced that it will host its Second Annual Analyst...

AXGN : 27.85 (+1.64%)
AxoGen, Inc. Reports 2017 Third Quarter Financial Results

AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the repair of peripheral nerve damage, today reported financial results and business highlights...

AXGN : 27.85 (+1.64%)
AxoGen, Inc. Receives David J. Gury Company of the Year Award from BioFlorida

AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, has received the BioFlorida David J. Gury Company of the Year Award....

AXGN : 27.85 (+1.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

AxoGen Corp. is a regenerative medicine company engaged in the development and commercialization of technologies for peripheral nerve reconstruction and regeneration. It offers products for the repair of peripheral nerve injuries. AxoGen Corp was formerly known as LecTec Corporation.

See More

Key Turning Points

2nd Resistance Point 27.93
1st Resistance Point 27.66
Last Price 27.85
1st Support Level 27.04
2nd Support Level 26.69

See More

52-Week High 31.70
Last Price 27.85
Fibonacci 61.8% 22.93
Fibonacci 50% 20.23
Fibonacci 38.2% 17.52
52-Week Low 8.75

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.